Accueil   Diary - News   All news PX’THERAPEUTICS ANNOUNCES THE SUCCESSFUL COMPLETION OF RGP41 GMP MANUFACTURING FOR MYMETICS

PX’THERAPEUTICS ANNOUNCES THE SUCCESSFUL COMPLETION OF RGP41 GMP MANUFACTURING FOR MYMETICS

PX’Therapeutics, a CDMO specializing in the development of recombinant proteins for human and animal health, is proud to announce the end of the rgp41 manufacturing campaign and batch certification for clinical application. This drug substance will be used by Mymetics to develop a new vaccine formulation, within the framework of the MACIVIVA project, sustained by the European Union’s Horizon 2020 research and innovation program and the Swiss State Secretariat for Education, Research and Innovation (SERI) for the Swiss based consortium partners.

 


Rgp41 protein is one of the HIV-1 gp41 derived antigens constituting Mymetics’ HIV-1 vaccine that is anchored to the membrane surface of the virosome particle, which acts as vaccine delivery vehicle for soliciting the immune system for inducing the production of protective serum and mucosal antibodies.

 

 

 

Read the press release